Jacobsen Stein Form 4 February 17, 2010

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 4 or Form 5 obligations may continue. See Instruction

Check this box

if no longer

Section 16.

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Jacobsen Stein

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

(Check all applicable)

Issuer

RESMED INC [RMD]

(Month/Day/Year)

02/12/2010

(First) (Middle) 3. Date of Earliest Transaction

Director

10% Owner

RESMED INC., 9001 SPECTRUM

CENTER BLVD.

(Last)

X\_ Officer (give title Other (specify below)

COO, Europe

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

SAN DIEGO, CA 92123

(City)	(State)	(Zip) Tab	ole I - Non-	Derivative	Secu	rities Acquii	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit oror Dispos (Instr. 3, 4	ed of	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Instr. 3 and 4)		
ResMed Common Stock	02/12/2010		M	12,000	A	\$ 38.5	14,376.063	D	
ResMed Common Stock	02/12/2010		S	12,000	D	\$ 55.6476 (2)	2,376.063	D	
ResMed Common Stock	02/12/2010		M	17,500	A	\$ 31.04	19,876.063	D	
ResMed Common	02/12/2010		S	17,500	D	\$ 55.6675	2,376.063	D	

(3) Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	orDeriv Secur Acqui	ities ired (A) sposed of . 3, 4,	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
ResMed Common Stock Options	\$ 38.5	02/12/2010		M		12,000	02/03/2007(1)	02/03/2016	ResMed Common Stock	12,00
ResMed Common Stock Options	\$ 31.04	02/12/2010		M		17,500	11/20/2009(1)	11/20/2015	ResMed Common Stock	17,50

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Jacobsen Stein						
RESMED INC.			COO,			
9001 SPECTRUM CENTER BLVD.			Europe			
SAN DIEGO, CA 92123						

# **Signatures**

Stein Jacobsen	02/17/2010			
**Signature of	Date			

2 Reporting Owners

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents first date options became exercisable.
- This transaction was executed in multiple trades at prices rangining from \$55.56 to \$55.74. The price reported reflects the weighted (2) average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.
- This transaction was executed in multiple trades at prices rangining from \$55.53 to \$55.74. The price reported reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.
- Previous reports aggregated all beneficially owned derivative securities following the reported transaction. This report includes only (4) beneficially owned derivative securities of the same class as those disposed of in this trade, meaning those that have the same grant date and exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.